DelveInsight’s “West Syndrome Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the West Syndrome, epidemiology insights, West Syndrome market trends, therapies, and key companies working in the West Syndrome Market in the 7MM.
West Syndrome Overview
West syndrome is a constellation of symptoms characterized by epileptic/infantile spasms, abnormal brain wave patterns called hypsarrhythmia, and intellectual disability. The spasms that occur may range from violent jackknife or “salaam” movements where the whole body bends in half, or they may be no more than a mild twitching of the shoulder or eye changes. These spasms usually begin in the early months after birth and can sometimes be helped with medication. They can also occur in older patients; if this happens, they are called “epileptic spasms” rather than infantile spasms. Currently, the International League Against Epilepsy (ILAE) has revised the terminology and epileptic spasms is now preferentially used to encompass the different age groups of onset. There are many different causes of epileptic spasms and if a specific cause can be identified, a diagnosis of symptomatic epileptic spasms can be made. If a cause cannot be determined, a diagnosis of cryptogenic epileptic spasms is made.
West Syndrome Epidemiology Insights
-
West syndrome has been estimated to affect 31 per 1000 live births in the United States. West syndrome accounts for approximately 30 percent of all cases of epilepsy affecting infants.
-
Only 5 out of every 100 children diagnosed with West syndrome will not survive beyond the age of five years.
Click here to learn more about the West Syndrome Market Landscape
The Report Covers the West Syndrome Epidemiology Segmented by:
-
Total West Syndrome incident cases
-
Total West Syndrome prevalent cases
-
Total West Syndrome treatment cases
-
Total West Syndrome diagnostic cases
West Syndrome Market Outlook
The West Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted West Syndrome market trends by analyzing the impact of current West Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the West Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated West Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the West Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the West Syndrome Market
-
Mallinckrodt Pharmaceuticals
-
INSYS Therapeutics
-
GW Pharmaceuticals
-
BioPharm Solutions
And many others
West Syndrome Therapies Covered and Analyzed in the Report
-
H.P. Acthar
-
Cannabidiol
-
Epidiolex
-
JBPOS0101
And many others
Learn more about the Key Companies and Emerging Therapies in the West Syndrome Market.
Table of Contents
-
Key Insights
-
West Syndrome Introduction
-
Executive Summary of West Syndrome
-
Disease Background and Overview
-
Epidemiology and patient population
-
West Syndrome Emerging Therapies
-
West Syndrome Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ West Syndrome Market Outlook.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services